Curcumin i mediates neuroprotective effect through attenuation of quinoprotein formation, p-p38 MAPK expression, and caspase-3 activation in 6-hydroxydopamine treated SH-SY5Y cells

Phytotherapy Research

Volumn 28, Issue 4, 2014, Pages 611-616

  Meesarapee, Benjawan ^a   Thampithak, Anusorn ^b   Jaisin, Yamaratee ^c   Sanvarinda, Pimtip ^a   Suksamrarn, Apichart ^d   Tuchinda, Patoomratana ^a   Morales, Noppawan Phumala ^a   Sanvarinda, Yupin ^a  

^a Mahidol University   (Thailand)

^b BURAPHA UNIVERSITY   (Thailand)

^c SRINAKHARINWIROT UNIVERSITY   (Thailand)

^d RAMKHAMHAENG UNIVERSITY   (Thailand)

Author keywords

6 OHDA; cleaved caspase 3; curcumin I; p TH; p38 MAPK; quinoprotein

Indexed keywords

CASPASE 3; CURCUMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDOPAMINE; PEPTIDES AND PROTEINS; QUINOPROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURCUMA LONGA; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; NERVE CELL CULTURE; NEUROPROTECTION; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

CURCUMA LONGA;

6-OHDA; CLEAVED CASPASE-3; CURCUMIN I; P-TH; P38 MAPK; QUINOPROTEIN;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CURCUMA; CURCUMIN; DOPAMINERGIC NEURONS; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOPAMINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TYROSINE 3-MONOOXYGENASE;

EID: 84898011829     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5036     Document Type: Article

References (32)

1. Blum D, Torch S, Lambeng N, et al,. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172.
2. Chan AS, Ng LW, Poon LS, et al,. 2007. Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress. Apoptosis 12 (1): 167-179.
3. Chandra J, Samali A, Orrenius S,. 2000. Triggering and modulation of apoptosis by oxidative stress. Free Radical Bio Med 29: 323-333.
4. Changtam C, de Koning HP, Ibrahim H, et al,. 2010. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem 45: 941-956.
5. Choi W-S, Eom D-S, Han BS, et al,. 2004. Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8 and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem 279 (19): 20451-20460.
6. Cohen G, Heikkila R,. 1974. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid and related cytotoxic agents. J Biol Chem 249: 2447-2452.
7. Graham DG,. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643.
8. Huot P, Levesque M, Parent A,. 2007. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 130: 222-232.
9. Jaisin Y, Thampithak A, Meesarapee B, et al,. 2011. Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis. Neurosci Lett 489: 192-196.
10. Joe B, Lokesh BR,. 1994. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta 1224: 255-263.
11. Kim EK, Choi EJ,. 2010. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405.
12. Kuhn DM, Arthur RE Jr, Thomas DM, Elferink LA,. 1999. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem 73: 1309-1317.
13. Lamkanfi M, Festjens N, Declercq W, et al,. 2007. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 14: 44-55.
14. Lotharius J, Dugan LL, O'Malley KL,. 1999. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 19: 1284-1293.
15. Luo Y, Hattori A, Munoz J, et al,. 1999. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-kappaB in rats. Mol Pharmacol 56: 254-264.
16. Machida Y, Chiba T, Takayanaki A, et al,. 2005. Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem Biophys Res Commun 332: 233-240.
17. Mansouri Z, Sabetkasei M, Moradi F, et al,. 2012. Curcumin has neuroprotection effect on homocysteine rat model of Parkinson. J Mol Science 47: 234-242.
18. Mu X, He G, Cheng Y, et al,. 2009. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental Parkinsonism in vivo and in vitro. Pharmacol Biochem Behav 92: 642-648.
19. Paz MA, Fluckiger R, Boak A, et al,. 1991. Specific detection of quinoproteins by redox-cycling staining. J Biol Chem 266: 689-692.
20. Rajeswari A, Sabesan M,. 2008. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology 16: 96-99.
21. Reed JC,. 2000. Mechanisms of apoptosis. Am J Pathol 157: 1415-1430.
22. Ruby AJ, Kuttan G, Babu KD, et al,. 1995. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94: 79-83.
23. Sachs C, Jonsson GS,. 1975. Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24: 1-8.
24. Saner A, Thoenen H,. 1971. Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol 7: 147-154.
25. Schapira AH, Cooper JM, Dexter D, et al,. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823-827.
26. Schuler M, Bossy-Wetzel E, Goldstein JC, et al,. 2000. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 275: 7337-7342.
27. Shishodia S, Singh T, Chaturvedi MM,. 2007. Modulation of transcription factors by curcumin. Adv Exp Med Biol 595: 127-148.
28. Thiyagarajan M, Sharma SS,. 2004. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 74: 969-985.
29. Toda S, Miyase T, Arichi H, et al,. 1985. Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull(Tokyo) 33: 1725-1728.
30. Ungerstedt U,. 1976. 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol Ther 2: 37-40.
31. Yadav RS, Sankhwar ML, Shukla RK, et al,. 2009. Attenuation of arsenic neurotoxicity by curcumin in rats. Toxicol Appl Pharmacol 240: 367-376.
32. Zbarsky V, Datla KP, Parkar S, et al,. 2005. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 39: 1119-1125.